Geneva Capital Management LLC Trims Position in Certara, Inc. (NASDAQ:CERT)

Geneva Capital Management LLC decreased its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 0.9% during the fourth quarter, HoldingsChannel reports. The firm owned 5,458,600 shares of the company’s stock after selling 51,609 shares during the period. Geneva Capital Management LLC’s holdings in Certara were worth $58,134,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Raymond James Financial Inc. purchased a new position in Certara during the 4th quarter valued at about $3,628,000. Proficio Capital Partners LLC purchased a new position in Certara during the 4th quarter valued at about $148,000. M&T Bank Corp increased its position in Certara by 41.9% during the 4th quarter. M&T Bank Corp now owns 163,933 shares of the company’s stock valued at $1,746,000 after purchasing an additional 48,381 shares during the period. Charles Schwab Investment Management Inc. increased its position in Certara by 8.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 757,392 shares of the company’s stock valued at $8,066,000 after purchasing an additional 57,817 shares during the period. Finally, Bank of New York Mellon Corp increased its position in Certara by 169.0% during the 4th quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company’s stock valued at $21,248,000 after purchasing an additional 1,253,385 shares during the period. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Wall Street Analyst Weigh In

CERT has been the topic of a number of research reports. Barclays raised their target price on shares of Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. Stephens restated an “overweight” rating and issued a $17.00 price target on shares of Certara in a report on Thursday, February 27th. TD Cowen started coverage on shares of Certara in a report on Thursday, February 27th. They issued a “buy” rating and a $16.00 price target on the stock. Finally, William Blair restated a “market perform” rating on shares of Certara in a report on Thursday, February 27th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Certara currently has a consensus rating of “Moderate Buy” and an average target price of $15.83.

Certara Stock Up 0.5 %

CERT stock opened at $11.91 on Thursday. The firm has a 50 day moving average of $12.52 and a 200 day moving average of $11.63. The stock has a market capitalization of $1.92 billion, a PE ratio of -59.55, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a 52 week low of $9.41 and a 52 week high of $19.87.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.